18889881171
Kalkine 0
countryflagUS

Amneal Pharmaceuticals, Inc. Class A Common Stock

Healthcare US AMRX

7.165USD
-0.105(1.44%)

Last update at 2025-05-22T16:56:00Z

Day Range

7.167.30
LowHigh

52 Week Range

4.469.47
LowHigh

Fundamentals

  • Previous Close 7.27
  • Market Cap3764.98M
  • Volume559876
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA566.76M
  • Revenue TTM2680.42M
  • Revenue Per Share TTM9.16
  • Gross Profit TTM 791.46M
  • Diluted EPS TTM-0.86

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -248.12700M 31.37M -35.78000M -220.24200M -202.72200M
Minority interest -125.24100M 9.55M -22.48100M 114.78M 391.61M
Net income -254.78900M 20.17M 68.58M -603.57300M -169.72600M
Selling general administrative 400.43M 365.70M 326.73M 289.60M 230.44M
Selling and marketing expenses - - - - -
Gross profit 784.71M 768.97M 628.39M 353.00M 716.40M
Reconciled depreciation 240.18M 233.41M 235.39M 207.24M 137.40M
Ebit 206.46M 209.24M 91.16M -137.42300M 278.37M
Ebitda 446.64M 442.64M 349.06M 69.81M 415.77M
Depreciation and amortization 240.18M 233.41M 257.90M 207.24M 137.40M
Non operating income net other 5.18M 14.97M 19.06M 196.65M -39.47800M
Operating income 206.46M 209.24M 91.16M -137.42300M -19.67300M
Other operating expenses 2023.38M 1899.76M 1881.44M 1765.26M 1387.47M
Interest expense 158.38M 136.32M 146.00M 168.21M 143.57M
Tax provision 6.66M 11.20M -104.35800M 383.33M -1.41900M
Interest income - - - 173.17M 163.27M
Net interest income -158.66800M -136.32500M -145.99800M -168.20500M -143.57100M
Extraordinary items - - - - 0.20M
Non recurring 288.68M 35.28M 21.59M 107.64M 89.93M
Other items - - - - -
Income tax expense 6.66M 11.20M -104.35800M 383.33M -1.41900M
Total revenue 2212.30M 2093.67M 1992.52M 1626.37M 1662.99M
Total operating expenses 595.79M 575.07M 517.31M 491.88M 440.89M
Cost of revenue 1427.60M 1324.70M 1364.13M 1273.38M 946.59M
Total other income expense net -454.59100M -177.87000M -126.93500M -82.81900M -334.66800M
Discontinued operations - - - - -
Net income from continuing ops -254.78900M 20.17M 68.58M -603.57300M -201.30300M
Net income applicable to common shares -129.98600M 10.62M 91.06M -361.91700M -20.92000M
Preferred stock and other adjustments 0.44M - - - 1.18M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3472.57M 3799.34M 3939.66M 4006.03M 3665.89M
Intangible assets 890.42M 1096.09M 1166.92M 1304.63M 1382.75M
Earning assets - - - - -
Other current assets 91.20M 103.56M 110.22M 73.47M 70.16M
Total liab 3452.79M 3590.41M 3572.69M 3661.10M 3319.10M
Total stockholder equity 19.78M 183.98M 366.97M 344.93M 346.79M
Deferred long term liab - 2.21M 1.60M 2.65M 3.10M
Other current liab 475.40M 109.96M 47.86M 7.56M 5.97M
Common stock 3.07M 3.04M 3.01M 3.00M 2.99M
Capital stock 3.07M 3.04M 3.01M 3.00M 2.99M
Retained earnings -490.17600M -406.18300M -276.19700M -286.82100M -377.88000M
Other liab - 97.12M 48.52M 87.27M 35.71M
Good will 598.63M 598.85M 593.02M 522.81M 419.50M
Other assets - 17.63M 473.70M 149.30M 16.45M
Cash 91.54M 25.98M 247.79M 341.38M 151.20M
Cash and equivalents - - - - -
Total current liabilities 846.60M 752.80M 677.24M 676.90M 550.41M
Current deferred revenue 398.41M - - - -
Net debt 2658.98M 2819.16M 2628.27M 2599.43M 2614.87M
Short term debt 227.62M 104.64M 46.04M 55.68M 36.95M
Short long term debt 213.12M 89.96M 30.61M 45.23M 21.48M
Short long term debt total 2750.52M 2845.14M 2876.06M 2940.81M 2766.07M
Other stockholder equity 539.24M 577.19M 664.98M 670.07M 721.74M
Property plant equipment - 469.81M 514.16M 477.75M 620.60M
Total current assets 1377.86M 1411.82M 1520.11M 1551.54M 1210.21M
Long term investments - - - - 16.37M
Net tangible assets - -1371.57600M -1382.69200M -1512.36500M -1570.24700M
Short term investments 2.20M - - - 1.12M
Net receivables 613.73M 742.29M 663.76M 640.30M 606.16M
Long term debt 2427.45M 2591.98M 2680.05M 2735.26M 2609.05M
Inventory 581.38M 530.74M 489.39M 490.65M 381.07M
Accounts payable 143.57M 538.20M 583.35M 613.66M 507.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - -114.44200M 6.63M 41.66M 114.78M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -32.34900M 9.94M -24.82700M -41.31800M -0.06800M
Additional paid in capital - - - - -
Common stock total equity - 3.04M 3.01M 3.00M 2.99M
Preferred stock total equity - - - - -
Retained earnings total equity - -406.18300M -276.19700M -286.82100M -377.88000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 18.43M 103.22M 20.61M 31.89M 44.27M
Deferred long term asset charges - - - - -
Non current assets total 2094.71M 2387.52M 2419.56M 2454.49M 2455.68M
Capital lease obligations 109.95M 123.49M 127.35M 123.88M 135.54M
Long term debt total - 2591.98M 2680.05M 2735.26M 2674.51M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -174.30900M -194.18200M -317.54600M -19.58000M -396.37800M
Change to liabilities 111.64M -46.28700M 1.95M -5.02900M -69.32500M
Total cashflows from investing activities -174.30900M -194.18200M -317.54600M -19.58000M -396.37800M
Net borrowings 83.34M -1.00000M 175.90M -27.00000M 486.33M
Total cash from financing activities -106.62000M -138.12200M 131.81M -45.83300M 287.68M
Change to operating activities 12.60M -17.02500M 35.37M 43.16M 5.59M
Net income -254.78900M 20.17M 68.58M -603.57300M -201.30300M
Change in cash -221.51200M -90.38200M 194.30M -65.95700M 140.86M
Begin period cash flow 256.74M 347.12M 152.82M 218.78M 77.92M
End period cash flow 35.23M 256.74M 347.12M 152.82M 218.78M
Total cash from operating activities 65.10M 241.82M 379.00M 1.71M 250.23M
Issuance of capital stock - - - - -
Depreciation 240.18M 233.41M 235.39M 207.24M 137.40M
Other cashflows from investing activities -127.90200M -146.45400M -261.10100M 27.60M -313.29000M
Dividends paid - - - 0.00000M 183.00M
Change to inventory -102.39600M -49.01500M -113.78200M -20.39300M -42.87500M
Change to account receivables -79.71700M -23.62100M 16.79M -132.72600M 89.08M
Sale purchase of stock -1.06000M 0.85M 0.32M 1.40M -7.61800M
Other cashflows from financing activities 15.99M -58.94300M 168.82M -16.56300M 1255.01M
Change to netincome 132.06M 112.48M 128.21M 655.81M 301.26M
Capital expenditures 90.59M 52.64M 66.19M 97.43M 97.09M
Change receivables -80.07100M -16.31000M 17.20M -133.66500M 100.01M
Cash flows other operating 250.06M 211.58M 268.16M 102.07M 156.60M
Exchange rate changes - - - - -
Cash and cash equivalents changes -215.82900M -90.48400M 193.26M -63.70800M 141.53M
Change in working capital -59.94500M -133.59300M -61.31800M -120.21700M 7.01M
Stock based compensation 31.85M 28.41M 20.75M 21.68M 167.60M
Other non cash items 107.81M 10.04M 19.96M 124.86M 148.96M
Free cash flow -25.49500M 189.18M 312.81M -95.72600M 153.14M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock		 -0.105 1.44% 7.17 - 6.30 1.40 86.10 1.89 14.09
ZTS
Zoetis Inc		 -1.27 0.79% 160.17 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.64 2.42% 25.80 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 130.47 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.01 0.10% 14.34 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Amneal Pharmaceuticals, Inc. Class A Common Stock

400 Crossing Boulevard, Bridgewater, NJ, United States, 08807

Key Executives

Name Title Year Born
Mr. Chirag K. Patel Co-Founder, Co-CEO, Pres & Director 1967
Mr. Chintu Patel R.Ph, R.Ph. Co-Founder, Co-CEO & Director 1972
Mr. Anastasios G. Konidaris Exec. VP & CFO 1967
Ms. Nikita Shah Exec. VP and Chief HR & Strategic Planning Officer 1978
Mr. Andrew S. Boyer Exec. VP & Chief Commercial Officer of Generics 1966
Mr. Anthony DiMeo Sr. Director of Investor Relations NA
Mr. Jason B. Daly Esq. Sr. VP, Chief Legal Officer & Corp. Sec. 1974
Mr. Sanjiv Patel Sr. VP of Operations NA
Dr. Nikunj Patel Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd NA
Mr. Sanjay Kumar Jain Ph.D. Pres of India Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.